For 2023, we returned $9.2 billion to shareholders via our quarterly dividend, we have invested $10.7 billion in internal R&D and finally, we have invested approximately $44 billion in completed business development transactions, net of cash acquired, essentially all for the acquisition of Seagen. ...
Pfizer Declares Second-Quarter 2025 DividendApr. 23BU Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual MeetingApr. 23BU Pfizer : Political Action Committee (PAC) Report January 2023 - December 2024Apr. 21PU
Get Pfizer Inc (PFE:NYSE) real-time stock quotes, news, price and financial information from CNBC.
Stock Screener ETF Screener Popular Penny Stock Screener Technical Analysis Screener Ideas Top Analyst Stocks Popular Top Smart Score Stocks Popular Top Insiders Stocks Research Tools Compare Stocks Compare ETFs Trending Stocks Daily Analyst Ratings Daily Insiders Trades Dividend Stocks ETF Center Top Gainer...
Latest on PFE: Multiple Alerts: AMD Stock Down And More The Savvy Investor 4.8Fear & Greed Trader Themes: Macro Asset Allocation Latest on PFE: MACRO Update - 2024 RESULTS The Dividend Freedom Tribe 4.9Robert & Sam Kovacs Themes: Dividend Stocks Retirement Latest on PFE: What Should Investors...
Microsoft Corporation Common Stock $394.39 +3.23+0.83% Trending ETFs Data as of Apr 29, 2025 10:07 AM ET QQQ Invesco Qqq Trust, Series 1 $474.20 +1.79+0.38% SPY Spdr S&P 500 $552.66 +1.81+0.33% SCHD Schwab Us Dividend Equity Etf ...
The historical dividend returns of Pfizer, Inc., including all percentage dividend increases and decreases for PFE stock.
Yes. So thank you very much for the question. So for oncology, as you stated, since the beginning of 2023, we had an end-to-end organization covering discovery, early-stage development, late-stage development as well as medical. And we already had that in vaccine since 2009. And now we...
During a conference in January, Bourla acknowledged that 2023 was a rough year for the company and its stock price.But he saidPfizer took steps to start 2024 with a "clean slate." Those includedrenegotiatingmultibillion-dollar Covid contracts with the EU and other governments, transitioning its...
Last year was a strong one in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to the decline in revenues and profits. It saw improved performance of its new products, gained and maintained market share of some of its core brands and made rapid...